NCT03072459

Brief Summary

A retrospective, multi-center, cohort study with prospective follow-up and comparison to historical control

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2017

Shorter than P25 for all trials

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 2, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 7, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

July 10, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 29, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 29, 2017

Completed
4.4 years until next milestone

Results Posted

Study results publicly available

May 2, 2022

Completed
Last Updated

May 25, 2022

Status Verified

December 1, 2021

Enrollment Period

5 months

First QC Date

March 2, 2017

Results QC Date

July 1, 2019

Last Update Submit

May 2, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluate the Navio™ System for Revisions at 2+ Years Post-surgical Implantation Survivorship

    Analysis of the absence of device revision (overall survivorship) outcomes assessed from Baseline through 120 weeks post-surgical implantation.

    Preoperative (Baseline) and 24, 48, 72, 96, and 120 weeks postoperatively

Secondary Outcomes (9)

  • Evaluation of Efficacy Based on Knee Society Score (KSS) Assessments

    Preoperative (Baseline) and 6, 12, 18, 24, 30, and 36 months postoperatively

  • Evaluation of Efficacy Based on Veterans RAND 12 (VR-12) Assessments

    Preoperative (Baseline) and 6, 12, 18, 24, 30, and 36 months postoperatively

  • Preoperative Evaluation of Efficacy Based on Radiographic Findings

    Preoperative (Baseline)

  • Postoperative 6-Month Evaluation of Efficacy Based on Radiographic Findings

    6 months postoperatively

  • Postoperative 12-Month Evaluation of Efficacy Based on Radiographic Findings

    12 months postoperatively

  • +4 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

One hundred twenty-eight (128) subjects, including 10% inflation to allow for attrition

You may qualify if:

  • Male or female subjects ≥ 18 years old (at the time of surgery) who have undergone Navio System-assisted UKR at least 2 years prior to enrollment. This includes UKR procedures with all Unicondylar Knee cemented implant designs.
  • Subject had a primary diagnosis of unicompartmental, non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis, required correction of functional deformity, or required treatment of fractures that were unmanageable using other techniques.

You may not qualify if:

  • Subject received the Navio System-assisted UKR on the index joint as a revision for a previously failed UKR.
  • Subject, in the opinion of the Investigator, had advanced osteoarthritis or joint disease at the time of surgery and was better suited for Total Knee Arthroplasty (TKA).
  • Subject, in the opinion of the Investigator, had a neuromuscular disorder that prohibited control of the index joint.
  • Subject, in the opinion of the Investigator, was morbidly obese.
  • Subject, in the opinion of the Investigator, was contraindicated for UKR.
  • Subject (prospective subjects only), in the opinion of the Investigator, has an emotional or neurological condition including mental illness, mental retardation, drug or alcohol abuse.
  • Subject (prospective subjects only) is a prisoner.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Hedley Orthopedics

Phoenix, Arizona, 85016, United States

Location

Santa Barbara Cottage Hospital

Santa Barbara, California, 93105, United States

Location

Bronson Orthopedic Specialists

Battle Creek, Michigan, 49015, United States

Location

OrthoNeuro New Albany

New Albany, Ohio, 43054, United States

Location

Rothman Institute

Philadelphia, Pennsylvania, 19107, United States

Location

Limitations and Caveats

There were no known study limitations.

Results Point of Contact

Title
Salima Reddy
Organization
Smith & Nephew, Inc.

Study Officials

  • Beate Hanson, MD, PhD

    Smith & Nephew, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2017

First Posted

March 7, 2017

Study Start

July 10, 2017

Primary Completion

November 29, 2017

Study Completion

November 29, 2017

Last Updated

May 25, 2022

Results First Posted

May 2, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations